A clinical-stage oncology biotechnology company using its Helicon peptide platform to drug historically undruggable targets, with lead asset zolucatetide (FOG-001) advancing toward Phase III in Wnt/beta-catenin-driven tumors.
A clinical-stage oncology biotechnology company using its Helicon peptide platform to drug historically undruggable targets, with lead asset zolucatetide (FOG-001) advancing toward Phase III in Wnt/beta-catenin-driven tumors.
